- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05795699
A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
February 29, 2024 updated by: Kowa Research Institute, Inc.
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy
A study to assess the safety and efficacy of K-321 in participants with FECD after descemetorhexis.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Director, Clinical Operations
- Phone Number: 919-433-1600
- Email: Clinical@KowaUS.com
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1K1
- Recruiting
- Dr. Greg Moloney
-
-
Ontario
-
Oakville, Ontario, Canada, L6H 0J8
- Not yet recruiting
- Prism Eye Institute - Mississauga-Oakville
-
Ottawa, Ontario, Canada, K1H 8L6
- Not yet recruiting
- Ottawa Hospital
-
Ottawa, Ontario, Canada, K1G 5L1
- Recruiting
- Precision Cornea Centre
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 2M4
- Not yet recruiting
- Hopital Maisonneuve-Rosemont (HMR)
-
Montreal, Quebec, Canada, H2X 0C1
- Not yet recruiting
- Centre Hospitalier de l'Université de Montréal
-
-
-
-
Capital
-
Glostrup, Capital, Denmark, 2600
- Recruiting
- Rigshospitalet Glostrup-Nordre Ringvej 57
-
-
Central Jutland
-
Aarhus N, Central Jutland, Denmark, 8200
- Not yet recruiting
- Aarhus Universitetshospital
-
-
-
-
-
Muenchen, Germany, 81377
- Not yet recruiting
- LMU Klinikum der Universität
-
-
Baden-Württemberg
-
Heidelberg, Baden-Württemberg, Germany, 69120
- Recruiting
- Universitätsklinikum Heidelberg
-
Tübingen, Baden-Württemberg, Germany, 72076
- Not yet recruiting
- Universitätsklinikum Tübingen
-
-
Bayern
-
Erlangen, Bayern, Germany, 91054
- Not yet recruiting
- Universitatsklinkum Erlangen-Ulmenweg 18
-
-
Nordrhein-Westfalen
-
Düsseldorf, Nordrhein-Westfalen, Germany, 40225
- Recruiting
- Universitätsklinikum Düsseldorf
-
Köln, Nordrhein-Westfalen, Germany, 50931
- Not yet recruiting
- Uniklinik Köln
-
-
Saarland
-
Homburg, Saarland, Germany, 66424
- Recruiting
- Universität des Saarlandes
-
-
Sachsen
-
Leipzig, Sachsen, Germany, 04103
- Recruiting
- Universitätsklinikum Leipzig
-
-
-
-
-
Barcelona, Spain, 08035
- Not yet recruiting
- Instituto de microcirugía ocular
-
Barcelona, Spain, 08017
- Not yet recruiting
- Oftalvist - Barcelona
-
Barcelona, Spain, 08022
- Not yet recruiting
- Institut Catala de Retina (ICR)
-
-
Asturias
-
Oviedo, Asturias, Spain, 33012
- Recruiting
- Instituto Oftalmologico Fernandez Vega
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Recruiting
- Hospital Universitario Germans Trias i Pujol
-
Manresa, Barcelona, Spain, 08243
- Recruiting
- Althaia Xarxa Assistencial Universitaria Manresa
-
-
Córdoba
-
Cordoba, Córdoba, Spain, 14012
- Recruiting
- Hospital Arruzafa
-
-
-
-
Lancashire
-
Liverpool, Lancashire, United Kingdom, L7 8XP
- Not yet recruiting
- The Royal Liverpool University Hospital
-
-
London, City Of
-
London, London, City Of, United Kingdom, EC1V 2PD
- Not yet recruiting
- Moorfields Eye Hospital
-
-
Northumberland
-
Newcastle Upon Tyne, Northumberland, United Kingdom, NE1 4LP
- Not yet recruiting
- Royal Victoria Infirmary
-
-
-
-
California
-
Los Angeles, California, United States, 90033
- Not yet recruiting
- Keck Hospital of USC
-
Los Angeles, California, United States, 90048
- Not yet recruiting
- Macy Eye Center
-
Los Angeles, California, United States, 90095
- Not yet recruiting
- Jules Stein Eye Institute
-
Palo Alto, California, United States, 94303
- Not yet recruiting
- Byers Eye Institute at Stanford
-
Sacramento, California, United States, 95815
- Not yet recruiting
- Sacramento Eye Consultants
-
-
Florida
-
Fort Myers, Florida, United States, 33907
- Recruiting
- Gorovoy MD Eye Specialists
-
Gainesville, Florida, United States, 32605
- Not yet recruiting
- University of Florida
-
Miami, Florida, United States, 33418
- Recruiting
- Bascom Palmer Eye Institute
-
Naples, Florida, United States, 34103
- Not yet recruiting
- Bascom Palmer Eye Institute - Naples
-
-
Kentucky
-
Lexington, Kentucky, United States, 40508
- Recruiting
- University of Kentucky
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105
- Not yet recruiting
- W Kellogg Eye Center
-
Grand Rapids, Michigan, United States, 49546
- Not yet recruiting
- Verdier Eye Center
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Active, not recruiting
- Tauber Eye Center
-
-
Nebraska
-
Omaha, Nebraska, United States, 68137
- Not yet recruiting
- Vance Thompson Vision - Omaha
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- Not yet recruiting
- Eye Associates of New Mexico
-
-
New York
-
New York, New York, United States, 10017
- Not yet recruiting
- NYU Langone Health
-
Slingerlands, New York, United States, 12159
- Not yet recruiting
- Cornea Consultants of Albany
-
-
North Dakota
-
W. Fargo, North Dakota, United States, 58078
- Not yet recruiting
- Vance Thompson Vision West Fargo
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Not yet recruiting
- University Hospitals Cleveland Medical Center - 11100 Euclid Ave
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Recruiting
- Devers Eye Institute
-
Portland, Oregon, United States, 97239
- Not yet recruiting
- Casey Eye Institute - OHSU
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, United States, 19004
- Active, not recruiting
- Ophthalmic Partners
-
-
Texas
-
Dallas, Texas, United States, 75390
- Not yet recruiting
- University of Texas Southwestern Medical Center
-
Houston, Texas, United States, 77025
- Not yet recruiting
- Houston Eye Associates
-
San Antonio, Texas, United States, 78229
- Not yet recruiting
- R and R Eye Research, LLC.
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53705
- Not yet recruiting
- University of Wisconsin - 2870 University Ave
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Is at least 18 years old at the screening visit (Visit 1)
- Has a diagnosis of FECD at Visit 1
- Meets all other inclusion criteria outlined in clinical study protocol
Exclusion Criteria:
Is a female patient of childbearing potential and any of the following is true:
- is pregnant or lactating/breastfeeding, or
- is not surgically sterile, not post-menopausal (no menses for the previous 12 months), or not practicing an effective method of birth control as determined by the Investigator (eg, oral contraceptives, double barrier methods, hormonal injectable or implanted contraceptives, tubal ligation, or partner with vasectomy)
- Has a study eye with a history of cataract surgery within 90 days of Visit 1
- Meet any other exclusion criteria outlined in clinical study protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: K-321
K-321 ophthalmic solution four times daily (QID) for 12 weeks followed by a two-week gradual dose taper phase and 38-week follow-up phase
|
K-321 ophthalmic solution
Other Names:
|
Placebo Comparator: Placebo
Placebo ophthalmic solution QID for 12 weeks followed by a two-week gradual dose taper phase and 38-week follow-up phase
|
Placebo ophthalmic solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to improvement in best corrected (distance) visual acuity (BCVA) by ETDRS letter score during the first 12 weeks
Time Frame: Baseline to Week 12
|
Baseline to Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to improvement in best corrected (distance) visual acuity (BCVA) by ETDRS letter score during the first 12 weeks
Time Frame: Baseline to Week 12
|
Baseline to Week 12
|
|
Time to achievement in best corrected (distance) visual acuity (BCVA) by ETDRS letter score during the first 12 weeks
Time Frame: Baseline to Week 12
|
Baseline to Week 12
|
|
Central corneal ECD at Week 12
Time Frame: Week 12
|
Central corneal endothelial cell images will be captured by non-contact specular microscopy.
|
Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Shona Pendse, MD, MMSc, Kowa Pharma Development Co.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 30, 2023
Primary Completion (Estimated)
March 1, 2024
Study Completion (Estimated)
January 1, 2025
Study Registration Dates
First Submitted
March 21, 2023
First Submitted That Met QC Criteria
March 21, 2023
First Posted (Actual)
April 3, 2023
Study Record Updates
Last Update Posted (Actual)
March 1, 2024
Last Update Submitted That Met QC Criteria
February 29, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- K-321-301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fuchs Endothelial Corneal Dystrophy
-
Kowa Research Institute, Inc.CompletedFuchs' Endothelial Corneal DystrophyUnited States, Australia, Germany, Spain, Denmark
-
Legacy Health SystemDevers Eye Institute; Lions Eye Bank of Oregon Vision Research Laboratory; Fischer...UnknownFuchs' Corneal Endothelial DystrophyUnited States
-
Massachusetts Eye and Ear InfirmaryRecruitingFuchs' Endothelial Corneal DystrophyUnited States
-
EmmecellRecruitingEndothelial Dysfunction | Corneal Edema | Fuchs Dystrophy | Corneal Endothelial Dystrophy | Bullous Keratopathy | Pseudophakic Bullous Keratopathy | Corneal Endothelial Dysfunction | Fuchs Endothelial Corneal Dystrophy | Moderate Corneal Endothelial DecompensationUnited States
-
State University of New York at BuffaloActive, not recruitingFuchs DystrophyUnited States
-
Centre Hospitalier Universitaire de Saint EtienneKyoto University, Graduate School of MedicineCompletedFuchs Endothelial Corneal DystrophyFrance
-
Charite University, Berlin, GermanyUnknownEndothelial Dysfunction | Bullous Keratopathy | Fuchs' Endothelial Corneal Dystrophy | Iridocorneal Endothelial Syndrome | Posterior Polymorphous DystrophyGermany
-
Trefoil Therapeutics, Inc.CompletedEndothelial Dysfunction | Corneal Endothelial Dystrophy | Pseudophakic Bullous Keratopathy | Fuchs Endothelial Corneal DystrophyUnited States
-
Cornea Research Foundation of AmericaCompletedBullous Keratopathy | Fuchs' Endothelial Corneal Dystrophy | Iridocorneal Endothelial Syndrome | Posterior Polymorphous DystrophyUnited States
-
Aarhus University HospitalCompletedFuchs' Endothelial Corneal DystrophyDenmark
Clinical Trials on Ripasudil
-
Asociación para Evitar la Ceguera en MéxicoEmmecellRecruitingEndothelial Dysfunction | Corneal Edema | Fuchs' Endothelial Dystrophy | Fuchs Dystrophy | Corneal Endothelial Dystrophy | Bullous Keratopathy | Pseudophakic Bullous Keratopathy | Corneal Edema PseudophakicMexico
-
Stanford UniversityUniversity of Pennsylvania; University of California, Davis; Oregon Health and... and other collaboratorsRecruiting
-
Stanford UniversityUniversity of Pennsylvania; University of California, Davis; Oregon Health and... and other collaboratorsRecruitingFuchs' Endothelial Dystrophy | Fuchs Dystrophy | FuchsUnited States
-
Singapore Eye Research InstituteRecruitingThe Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract SurgeryCataract | Fuchs' Endothelial DystrophySingapore
-
Kowa Research Institute, Inc.RecruitingFuchs Endothelial Corneal DystrophyGermany, United States, United Kingdom, Spain, Canada, Denmark
-
Kowa Research Institute, Inc.CompletedA Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract SurgeryCorneal Edema After Cataract SurgeryUnited States, Puerto Rico
-
University of Erlangen-Nürnberg Medical SchoolUnknownFuchs' Endothelial Dystrophy | Fuchs Dystrophy | Corneal Endothelial Dystrophy | Corneal Endothelial Cell Loss | Cornea GuttataGermany
-
Kyushu UniversityCompletedRetinopathy of PrematurityJapan
-
Marian Macsai, MDRecruitingFuchs' Endothelial DystrophyUnited States
-
Aerie PharmaceuticalsCompletedPrimary Open Angle Glaucoma | Ocular HypertensionJapan